SELLAS Ownership Just Shifted Before the 80-Event Catalyst-Now It's About Who Really Has Skin in the Game

SELLAS enters the catalyst window with more cash than credibility in the register

SELLAS has roughly $115 million of cash support as it heads toward the REGAL trial's 80th event, but its shareholder base is smaller and less entrenched than that balance sheet might suggest. Add $107.1 million in cash and cash equivalents to the $7.5 million in proceeds received in Q2 2026, and management has enough air cover to reach the finish line. Yet the company still only has a US$24m market capitalization. That creates the core tension: enough liquidity to get to the catalyst, but a small enough market cap that ownership quality can still drive sharp price swings.

The REGAL trial is already at 78 events on the path to its pre-specified 80th event, so this is no longer a distant biotech story. The readout window is close enough that positioning is happening now. In a stock this small, the durability of any move often depends less on the headline and more on who actually wants to hold through it.

A thinner register can cut both ways. If the data are positive, fewer committed holders can amplify upside. If they are disappointing, the same fragility can lead to a faster unwind. The key point is simple: with the catalyst near, the more useful question is not who is watching SELLAS, but who still has capital at risk.